Success Metrics

Clinical Success Rate
75.0%

Based on 18 completed trials

Completion Rate
75%(18/24)
Active Trials
8(19%)
Results Posted
39%(7 trials)
Terminated
6(14%)

Phase Distribution

Ph not_applicable
5
12%
Ph phase_2
18
43%
Ph phase_3
8
19%
Ph phase_4
5
12%
Ph early_phase_1
1
2%
Ph phase_1
3
7%

Phase Distribution

4

Early Stage

18

Mid Stage

13

Late Stage

Phase Distribution40 total trials
Early Phase 1First-in-human
1(2.5%)
Phase 1Safety & dosage
3(7.5%)
Phase 2Efficacy & side effects
18(45.0%)
Phase 3Large-scale testing
8(20.0%)
Phase 4Post-market surveillance
5(12.5%)
N/ANon-phased studies
5(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.2%

18 of 26 finished

Non-Completion Rate

30.8%

8 ended early

Currently Active

8

trials recruiting

Total Trials

42

all time

Status Distribution
Active(10)
Completed(18)
Terminated(8)
Other(6)

Detailed Status

Completed18
Recruiting7
unknown6
Terminated6
Not yet recruiting2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
42
Active
8
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.5%)
Phase 13 (7.5%)
Phase 218 (45.0%)
Phase 38 (20.0%)
Phase 45 (12.5%)
N/A5 (12.5%)

Trials by Status

completed1843%
recruiting717%
active_not_recruiting12%
unknown614%
not_yet_recruiting25%
withdrawn25%
terminated614%

Recent Activity

Clinical Trials (42)

Showing 20 of 42 trialsScroll for more
NCT07561125Phase 2

Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below

Recruiting
NCT02205762Phase 2

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Active Not Recruiting
NCT06925360Phase 2

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Recruiting
NCT03630211Phase 2

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

Recruiting
NCT07202052Phase 2

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)

Recruiting
NCT03994783Phase 3

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments

Terminated
NCT03194815Phase 2

IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2

Recruiting
NCT05114941Not Applicable

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome

Not Yet Recruiting
NCT05520892Phase 4

Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children

Recruiting
NCT04656184Phase 3

A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

Recruiting
NCT06183008Phase 4

IVIG in Painful Sensory Neuropathy

Not Yet Recruiting
NCT03401073Phase 2

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Completed
NCT05604859Phase 4

Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)

Unknown
NCT05104762Phase 2

IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients

Completed
NCT05634824Phase 2

IVIg Plus Low Dose rhTPO for ITP in Pregnancy

Unknown
NCT05134792Phase 2

Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients

Completed
NCT04035135Phase 1

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Completed
NCT02414490

IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements

Completed
NCT04261426Phase 2

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia

Unknown
NCT02586051Phase 1

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Completed

Drug Details

Intervention Type
DRUG
Total Trials
42